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suitability for use as a biomarker in DMOAD development. If suc- 
cessful, these methods could both accelerate the early evalua- 
tion of new molecules and demonstrate preservation on cartilage 
composition to support regulatory submission for licensure. 
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SERUM AND URINE BIOCHEMICAL MARKERS FOR USE 
IN OSTEOARTHRITIS CLINICAL TRIALS 
Joanne M Jordan 
Using radiographic outcomes, clinical trials of potential disease 
modifying interventions for development and progression of os- 
teoarthritis, typically last 2 to 3 years. Such trials are expensive, 
difficult o perform, and subject to biases from attrition and other 
methodologic problems. Inability to accurately identify individu- 
als likely to progress, for selection into a disease-modification 
trial, can limit statistical power if insufficient numbers of individ- 
uals develop the outcome under study. More sensitive imaging 
measures of OA outcome, such as magnetic resonance imaging, 
have been discussed. Biochemical markers, measured in serum 
or urine, are also under investigation to substitute for radiographic 
or other OA outcomes that might require a longer trial duration, 
and to help identify individuals whose OA is likely to develop or 
progress quickly. If a biomarker or panel of biomarkers, in con- 
junction with clinical or other easily obtainable measures, were 
able to identify individuals at high risk of rapid OA progression or 
were to predict response to intervention early, then the duration, 
number of study participants, and expense of clinical trials could 
be decreased and efficiency enhanced. 
In 2003, the NIH/NIAMS established The Osteoarthritis Biomark- 
ers Network as an international consortium of five sites engaged 
in innovative approaches to biomarker development and testing 
in OA. This consortium is working to develop a classification 
scheme for OA biomarkers that could provide a consistent ter- 
minology and framework to facilitate research, development, and 
validation of biomarkers. This classification scheme, still under 
development, proposes five categories of markers: 1)Investiga- 
tive; 2) Diagnostic; 3) Burden of disease, encompassing mea- 
sures of disease activity and damage; 4) Prognostic, and 5) Effi- 
cacy (and toxicity) of intervention. These classification categories 
are not mutually exclusive, nor do they necessarily imply that a 
marker must move serially through each of the categories in its 
development. Markers can fulfill criteria in more than one cate- 
gory. This proposed classification scheme, criteria for the cate- 
gories, and examples of current serum and urine biomarkers in 
each category will be discussed. 
7 
GRADING SYSTEM FOR MOUSE OSTEOARTHRITIS 
Qian Chen, Sonya S Glasson 
In recent years, knockout and transgenic mouse has become a 
widely used model to determine the contribution of a specific 
gene to the development of a disease in viva. Many genes have 
been implicated in the pathogenesis of osteoarthritis (OA). How- 
ever, unlike the OA occurring in human joint cartilage, there is 
no standardized grading system to evaluate the progress of OA 
in mouse joint cartilage. The lack of a uniform mouse OA grading 
system has made comparison of different mouse OA models diffi- 
cult. The goal of this session is to gather the researchers who are 
working in the mouse OA field, and develop a mouse OA grading 
standard that is accepted by the research community. Such stan- 
dardized mouse OA grading system will become a guideline to 
assess the severity of OA in mouse joint cartilage. This session 
will consist of three parts. 
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IDENTIFICATION OF TARGETS THROUGH HISTOLOGIC 
EVALUATION OF OSTEOARTHRITIS IN KNOCK OUT 
MICE 
Sonya Glasson 
Introduction: There are no disease-modifying osteoarthritis 
drugs (DMOADs) currently available for the treatment of OA. In 
order to identify which enzymes or cytokines are important in 
viva, studies were performed in knock out (KO) mice that were 
challenged in a surgical instability model. Those KOs showing a 
decrease in OA severity, following histologic evaluation would be 
targets for the development of selective inhibitors. 
Methods: In an IACUC-approved protocol, 12 different 10- 
week old knock-out (KO) and strain-specific wild-type (WT) mice 
had surgical instability induced in their right knees via desta- 
bilization of the medial meniscus (DMM). IL-11~ (B10.RIII WT), 
MMP-3 (B10.RIII WT), COX-l, COX-2 (B6;129) KOs were from 
Taconic. Jak-3 (C57BL6) and MMP-9 KO (FVB/N WT) mice were 
from Jackson Laboratories (Bar Harbor, ME). MMP-12, cPLA2~ 
(C57BL/6 WT), MK2 (DBA), ADAMTS-4, -5, 4/5 (129SvEv WT) 
KO mice were from Wyeth. Ten males per experimental group 
were sacrificed 8 weeks post-operatively. Knees were fixed in 
4% paraformaldehyde, decalcified, stained with Safranin-O and 
scored by 2 blinded observers using a modified semi-quantitative 
system (Chambers et al. 1997) where a higher score reflects 
greater OA severity. Histologic scores were obtained from all four 
quadrants of the joint (MFC, MTP, LFC, LTP)across 12-16 levels 
spaced at 80 i~m intervals. Results were expressed as a sum of 
all scores and could also be expressed as maximal scores across 
the entire joint or within a specific location (MTP). 
Results: Severity of OA varied greatly depending on the WT 
strain, with the most severe OA in the 129/SvEv strain, fol- 
lowed by C57B10.RIII, C57BL/6, FVB/N and DBA. There were 
no differences between MMP-3, COX-l, COX-2, Jak-3, MMP-12, 
cPLA20~, or ADAMTS-4 KO mice and their respective wild-type 
controls. The MMP-9 and MK2 KO mice had higher scores, re- 
flecting more severe OA, than their WT controls. The scores in 
the IL-11~, ADAMTS-5 and ADAMTS-4/5 KOs were significantly 
decreased compared to controls, using any variation of the scor- 
ing scheme, although greater sensitivity was observed using the 
summed method. 
Discussion: Histologic evaluation of mouse knee joints following 
surgical instability is sensitive to the effects of strain and to dis- 
ease modification from IL-11~ or ADAMTS-5 deletion. More severe 
OA could be observed in MMP-9 or MK2 deficient mice, suggest- 
ing that these enzymes could play a protective role, or that other 
enzymes are up-regulated to compensate. The deletion of the 
majority of genes examined showed no impact on the progres- 
sion of OA, suggesting that these have an insignificant role in OA 
progression. 
9 
DESIGN AND CONDUCT OF CLINICAL TRIALS IN 
OSTEOARTHRITIS 
Marc C Hochberg 
The Osteoarthritis Research Society International has published 
recommendations for the conduct of clinical trials in patients with 
hip or knee osteoarthritis (1) and is developing similar recommen- 
dations for patients with hand osteoarthritis. This session will re- 
view the design of randomized clinical trials focusing on 1) types 
of trials (superiority, equivalence, non-inferiority), 2) types of con- 
trols (placebo, active treatment), 3) inclusion criteria (including 
use of American College of Rheumatology [ACR] classification 
criteria for case definition), 4) exclusion criteria, 5) types of in- 
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terventions (pharmacologic and non-pharmacologic), 6) types of 
outcome measures (self-reported, performance-based, examina- 
tion, imaging), and 7) considerations in the statistical analysis of 
data. Participants will complete an exercise that designs a clinical 
trial for symptom and structure modification in patients with knee 
osteoarthritis. 
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ROLE OF MATRIX METALLOPROTEINASES IN 
CARTILAGE AND BONE DURING SKELETAL 
REMODELING 
Stephen M Krane 
Matrix metalloproteinases (MMPs) are expressed in cartilage dur- 
ing embryonic development and later during remodeling. Mmp9, 
although not a collagenase is expressed early in embryogen- 
esis during endochondral ossification and Mmp9 deficiency in 
mice results in abnormalities that affects growth plates. Mmp13 
(collagenase-3), a highly expressed collagenolytic MMP in carti- 
lage and in developing and remodeling bone, also has a role in 
the joint tissue destruction that is a major feature of various forms 
of human arthritis. We have targeted a null mutation in mouse 
Mmp13 that resulted in a profound embryonic and adult skeletal 
phenotype characterized by abnormal growth plates and delayed 
ossification. During embryonic development at the earliest stage 
examined, Mmp13 -/- mice had growth plates in long bones al- 
most double in length, accounted for by increases in the zone of 
hypertrophy. Mmp13, produced by chondrocytes but not by os- 
teoclasts/chondroclasts, i  particularly effective in proteolysis of 
type II compared to type I collagen. Using antibodies that detect 
epitopes in the specific proteolytic fragments, we obtained evi- 
dence for Mmp13 cleavage of type II collagen in vivo in wt mice, 
but not in Mmp13-/-mice. It is thus unlikely that other Mmps com- 
pensate for the loss of Mmp13 function in cartilage. The delay 
in ossification, so prominent in 15.5 dpc Mmp13 -/- embryos, is 
largely transient and older Mmp13 -/- mice have increased bone 
deposition. Mmp8 is also expressed in newborn Mmp13 -/- and wt 
skeletons but Mmp '-/- mice have normal skeletons. Type X colla- 
gen is also a substrate for MMP1 and Mmp13. The area of type X 
collagen deposition was significantly increased in growth plates 
from Mmp13-/-mice, consistent with decreased proteolysis. In- 
creased synthesis of type X collagen could also contribute. Based 
on our results, Mmp13 has a critical role in regulating events in 
the growth plate beginning in embryonic development. Deficiency 
of Mmpl 3 with failure to normally resorb collagens in the cartilage 
ECM profoundly affects cellular activities that underlie differenti- 
ation of hypertrophic hondrocytes that persist in newborn and 
adult mice. The phenotype of / adult Mmp13--mice with increased 
length of growth plates, increased numbers of chondrocytes and 
distortion of alignment of the rows of chondrocytes thus has fea- 
tures of a chondrodysplasia. Articular cartilage is also affected. 
It is pertinent hat a form of human chondrodysplasia, the Mis- 
souri variant of spondyloepimetaphyseal dysplasia is caused by a 
mutation in MMP13 that results in misfolding, intracellular degra- 
dation and MMP13 deficiency. Human mutations in MMP2 also 
result in a skeletal phenotype (nodulosis, osteolysis and arthropa- 
thy) distinct from that in MMP13 mutations. Bone is abnormal in 
Mmp2-null mice but the mice do not show other features of the 
human mutation. 
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INTEGRIN-SYNDECAN CO-OPERATION GOVERNS THE 
ASSEMBLY OF SIGNALLING COMPLEXES DURING CELL 
MIGRATION 
Martin J Humphries 
Cell adhesion receptors play a fundamental role in integrating the 
extracellular matrix with cell signalling complexes, and thereby 
control diverse, distal events in metazoa such as cell fate and 
tissue structure. Within cells, adhesion signalling occurs at focal 
sites and involves the formation and maturation of discrete ad- 
hesion complexes. The sequential modulation of Rho family GT- 
Pase activity is a critical control point determining the efficacy 
of adhesion signalling. Adhesive responses to the extracellular 
matrix protein, fibronectin (FN), which are mediated by members 
of the integrin and syndecan adhesion receptor families, have 
served as a prototype for many of these studies, and the out- 
comes are generally applicable to a large majority of adhesive re- 
sponses. Interestingly, cells plated onto a FN fragment hat binds 
the integrin ~51~1 are able to spread but fail to form adhesion com- 
plexes or fully organise actin into bundled stress fibres unless co- 
stimulated with a distinct FN fragment hat binds syndecan-4. En- 
gagement of syndecan-4 in such pre-spread cells recapitulates 
the Rho family activation profiles observed during spreading on 
whole FN. We have found that adhesion to a ligand of ~51~1 alone 
does not activate one member of the Rho family, Racl, indicating 
that engagement of syndecan-4 is an absolute requirement for 
this key signalling event. In related work, we have examined iffer- 
ences in the mechanism of adhesion complex formation mediated 
by different FN-binding integrins, ~41~1 and ~51~1. Two signalling 
differences were found. First, while ~51~1 required a proteoglycan 
co-receptor (syndecan-4), ~41~1 did not. Second, adhesion con- 
tact formation via ~51~1 required PKC~ activation, but only basal 
PKC~ activity was observed following adhesion via ~41~1. These 
findings demonstrate that different integrins can signal to induce 
focal adhesion formation and migration by different mechanisms, 
and provide insights into the ways that the extracellular environ- 
ment controls cell morphology and movement. 
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NOVEL GENETIC MARKERS OF OSTEOARTHRITIS 
John Loughlin 
Early cross-sectional and longitudinal studies demonstrated fa- 
milial clustering of primary osteoarthritis, implying a genetic com- 
ponent to the disease. However, such clustering could also be the 
result of shared environmental factors within a family. Twin studies 
have since been performed that demonstrate a clear heritability to 
OA at a number of skeletal sites, including hands, hips, knees and 
the spine [1]. Other epidemiological studies have also been per- 
formed investigating the nature of OA transmittance from parents 
to offspring and the prevalence of disease between relative-pairs, 
particularly siblings. These studies have confirmed a major ge- 
netic component o OA, which is transmitted in a non-Mendelian, 
complex manner. It has gradually become apparent hat the na- 
ture of the genetic risk is likely to vary somewhat between differ- 
ent skeletal sites and may also vary between the sexes, although 
this latter observation is based on a small number of studies and 
needs further investigation to confirm it's veracity. 
With a genetic component established the next step was a hunt 
for the risk alleles. Investigators initially focussed on genes en- 
coding the major structural components of the cartilage extracel- 
lular matrix, such as aggrecan and type II collagen. These stud- 
ies did not provide the expected breakthroughs and prompted a 
re-think on the nature of OA susceptibility: instead of the carti- 
lage matrix being poorly constructed could the susceptibility be 
